Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003

Detalles Bibliográficos
Autores principales:	Patrick, K, Wade, R, Goulden, N, Mitchell, C, Richards, S, Rowntree, C, Hough, R, Vora, A
Formato:	Journal article
Publicado:	2013

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
por: Patrick, K, et al.
Publicado: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
por: Patrick, K, et al.
Publicado: (2014)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
por: Vora, A, et al.
Publicado: (2012)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
por: Vora, A, et al.
Publicado: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
por: Vora, A, et al.
Publicado: (2013)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
por: Vora, A, et al.
Publicado: (2008)

Outcome of Thrombosis in UKALL 2003-Anticoagulation and Re-Exposure to Aspariginase Is Feasible and Safe.
por: Qureshi, A, et al.
Publicado: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
por: Vora, A, et al.
Publicado: (2008)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
por: Vora, A, et al.
Publicado: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
por: Vora, A, et al.
Publicado: (2014)

PROSPECTIVE EVALUATION OF QUALITY OF LIFE (QOL) IN CHILDREN TREATED IN UKALL 2003 FOR ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL): A COHORT STUDY
por: Eiser, C, et al.
Publicado: (2012)

Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
por: Qureshi, A, et al.
Publicado: (2010)

Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial
por: Jenkinson, S, et al.
Publicado: (2012)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
por: Samarasinghe, S, et al.
Publicado: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
por: Samarasinghe, S, et al.
Publicado: (2013)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
por: Vora, A, et al.
Publicado: (2010)

Prospective evaluation of quality of life in children treated in UKALL 2003 for Acute Lymphoblastic Leukaemia (ALL): A cohort study
por: Eiser, C, et al.
Publicado: (2017)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
por: O'Connor, D, et al.
Publicado: (2014)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
por: Vora, A, et al.
Publicado: (2008)

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
por: Jenkinson, S, et al.
Publicado: (2013)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
por: O'Connor, D, et al.
Publicado: (2014)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
por: Cutting, R, et al.
Publicado: (2008)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
por: Cutting, R, et al.
Publicado: (2009)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
por: Tomlins, J, et al.
Publicado: (2012)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
por: Moorman, A, et al.
Publicado: (2013)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
por: Patrick, K, et al.
Publicado: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
por: Patrick, K, et al.
Publicado: (2014)

Intramuscular PEG-Asparaginase At 1000 U/m(2) Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol
por: Fong, C, et al.
Publicado: (2011)

P343: GENOMIC CHARACTERISATION OF B-OTHER ALL IN UKALL2003 PATIENTS BY NEXT GENERATION SEQUENCING
por: C. Schwab, et al.
Publicado: (2022-06-01)

Improved survival with early intensification: combined results from the Medical Research Council Childhood ALL randomised trials, UKALL X and UKALL XI
por: Richards, S, et al.
Publicado: (1998)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Juan Chen, et al.
Publicado: (2023-01-01)

P329: UNRAVELING THE ROLE OF GATA3 IN EARLY HUMAN T CELL DEVELOPMENT AND EARLY T CELL PRECURSOR ALL (ETP-ALL)
por: N. Lambrechts, et al.
Publicado: (2022-06-01)

Emerging Necessity of Myeloid Mutational Analysis in Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)
por: Hamza Tariq, et al.
Publicado: (2023-08-01)

The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) – Mechanisms and Opportunities.
por: Kathrin Maria Bernt, et al.
Publicado: (2016-05-01)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
por: Vora, A, et al.
Publicado: (2005)

Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
por: Hann, I, et al.
Publicado: (2000)

Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL)
por: Schwab, C, et al.
Publicado: (2012)

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol
por: Sara Aslam, et al.
Publicado: (2021-12-01)

Characteristics and outcome of children and young adults with Early T-Precursor (ETP) ALL treated on UKALL 2003

Ejemplares similares

Ejemplares similares